Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2020

01-12-2020 | Thrombocytopenia | Research article

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival

Authors: Hamideh Salimzadeh, Elinor Bexe Lindskog, Bengt Gustavsson, Yvonne Wettergren, David Ljungman

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

Single nucleotide polymorphisms (SNPs) in DNA repair genes have a potential clinical value in predicting treatment outcomes. In the current study, we examined the association of SNPs in the genes XRCC1-rs25487, ERCC1-rs11615, ERCC2-rs238406, and ERCC2-rs13181 with colorectal cancer (CRC) risk, relapse-free survival (RFS), overall survival (OS), and toxicity during chemotherapy.

Methods

SNPs were analysed in 590 CRC cases and 300 controls using TaqMan technology. The association of SNPs with CRC risk and toxicity during chemotherapy was analysed using Chi2 test. The Kaplan–Meier method and log-rank test was used to measure the effects of the SNPs on RFS and OS.

Results

The CC genotype of ERCC2-rs238406 and the ERCC2-rs13181 C allele were associated with a significantly increased risk of CRC. The ERCC1-rs11615 genotype T/T was associated with stomatitis in adjuvant chemotherapy (p = 0.03). Also, more patients with the ERCC2-rs13181 C allele needed dose reduction compared to patients with the A/A genotype (p = 0.02). In first line chemotherapy, more patients with the ERCC1-rs11615 C allele suffered from nausea compared to those with the T/T genotype (p = 0.04) and eye reactions and thrombocytopenia were more common in patients with the ERCC2-rs13181 C allele compared to the A/A genotype (p = 0.006 and p = 0.004, respectively). ERCC2- rs238406 C/C was also associated with a higher frequency of thrombocytopenia (p = 0.03). A shorter 5-year OS was detected in stage I & II CRC patients with the ERCC2- rs238406 C allele (p = 0.02). However, there was no significant association between the SNPs and 5-year RFS.

Conclusions

Both SNPs in ERCC2 were associated with risk of CRC as well as toxicity during first line treatment. In addition, ERCC2- rs238406 was linked to OS in early stage CRC. The ERCC1-rs11615 variant was associated with toxicity during adjuvant chemotherapy. The results add support to previous findings that SNPs in ERCC1 and ERCC2 have a prognostic and predictive value in clinical management of CRC.
Appendix
Available only for authorised users
Literature
1.
Safiri S, Sepanlou SG, Ikuta KS, Bisignano C, Salimzadeh H, Delavari A, et al. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):913–33.CrossRef
2.
Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer. 2007;97(8):1021.PubMedPubMedCentralCrossRef
3.
Yamaguchi NH, Mayer IA, Malzyner A, de Andrade CJ, Murad AM, del Giglio A, et al. Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. J Gastrointest Oncol. 2014;5(1):57.PubMedPubMedCentral
4.
Piedbois P, Buyse M, Rustum Y, Machover D, Erlichman C, Carlson R, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate by the advanced colorectal cancer meta-analysis project. J Clin Oncol. 1992;10(6):896–903.CrossRef
5.
André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.PubMedCrossRef
6.
Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz H-J, Kim H-J, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res. 2011;17(6):1632–40.PubMedPubMedCentralCrossRef
7.
Ma S-C, Zhao Y, Zhang T, Ling X-L, Zhao D. Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis. Onco Targets Ther. 2015;8:641.PubMedPubMedCentral
8.
Dai Q, Luo H, Li XP, Huang J, Zhou TJ, Yang Z-H. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population. Mutagenesis. 2015;30(3):441–9.PubMedCrossRef
9.
Gebhardt F, Zänker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem. 1999;274(19):13176–80.PubMedCrossRef
10.
Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60(24):6921–6.PubMed
11.
Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz H-J. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 2001;61(24):8654–8.PubMed
12.
Wilson MD, Ruttan CC, Koop BF, Glickman BW. ERCC1: a comparative genomic perspective. Environ Mol Mutagen. 2001;38(2–3):209–15.PubMedCrossRef
13.
Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291–5.PubMedCrossRef
14.
Petit C, Sancar A. Nucleotide excision repair: from E. coli to man. Biochimie. 1999;81(1–2):15–25.PubMedCrossRef
15.
Lu X, Xiao S, Jin C, van der Straaten T, Li X. ERCC1 and XPD/ERCC2 polymorphisms’ predictive value of Oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis. J Clin Lab Anal. 2012;26(1):10–5.PubMedCrossRef
16.
Chang PM, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci. 2009;100(2):278–83.PubMedCrossRef
17.
18.
Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15(8):1194–203.PubMedCrossRef
19.
Lv H, Li Q, Qiu W, Xiang J, Wei H, Liang H, et al. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer. Pathol Oncol Res. 2012;18(4):1009–14.PubMedCrossRef
20.
Zhang L, Zhao J, Yu B, Song X, Sun G, Han L, et al. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients. Cancer Genet. 2017;218:51–7.PubMedCrossRef
21.
Zaanan A, Dalban C, Emile J-F, Blons H, Fléjou J-F, Goumard C, et al. ERCC1, XRCC1 and GSTP1 single nucleotide polymorphisms and survival of patients with colon cancer receiving oxaliplatin-based adjuvant chemotherapy. J Cancer. 2014;5(6):425–32.PubMedPubMedCentralCrossRef
22.
Le Morvan V, Smith D, Laurand A, Brouste V, Bellott R, Soubeyran I, et al. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics. 2007;8(12):1693–703.PubMedCrossRef
23.
Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American joint committee on cancer prognostic factors consensus conference: colorectal working group. Cancer. 2000;88(7):1739–57.PubMedCrossRef
24.
25.
Zeng F-R, Ling Y, Yang J, Tian X-C, Yang X, Luo R-C. X-ray repair cross-complementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer: a meta-analysis. Tumor Biol. 2013;34(1):555–63.CrossRef
26.
Yang H, Li G, Li W. Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer. Genet Mol Res. 2015;14(1):700–5.PubMedCrossRef
27.
Liu L, Miao L, Ji G, Qiang F, Liu Z, Fan Z. Association between XRCC1 and XRCC3 polymorphisms and colorectal cancer risk: a meta-analysis of 23 case–control studies. Mol Biol Rep. 2013;40(6):3943–52.PubMedCrossRef
28.
Karam RA, Al Jiffry BO, Al Saeed M, El Rahman TMA, Hatem M, Amer MG. DNA repair genes polymorphisms and risk of colorectal cancer in Saudi patients. Arab J Gastroenterol. 2016;17(3):117–20.PubMedCrossRef
29.
Qin C-J, Xu K-W, Chen Z-H, Zhai E-T, He Y-L, Song X-M. XRCC1 R399Q polymorphism and colorectal cancer risk in the Chinese Han population: a meta-analysis. Tumor Biol. 2015;36(2):461–6.CrossRef
30.
Forat-Yazdi M, Gholi-Nataj M, Neamatzadeh H, Nourbakhsh P, Shaker-Ardakani H. Association of XRCC1 Arg399Gln polymorphism with colorectal cancer risk: a HuGE meta analysis of 35 studies. Asian Pac J Cancer Prev. 2015;16(8):3285–91.PubMedCrossRef
31.
32.
Skjelbred CF, Sæbø M, Nexø BA, Wallin H, Hansteen I-L, Vogel U, et al. Effects of polymorphisms in ERCC1, ASE-1 and RAI on the risk of colorectal carcinomas and adenomas: a case control study. BMC Cancer. 2006;6(1):175.PubMedPubMedCentralCrossRef
33.
34.
Hou R, Liu Y, Feng Y, Sun L, Shu Z, Zhao J, et al. Association of single nucleotide polymorphisms of ERCC1 and XPF with colorectal cancer risk and interaction with tobacco use. Gene. 2014;548(1):1–5.PubMedCrossRef
35.
Lamas MJ, Duran G, Balboa E, Bernardez B, Touris M, Vidal Y, et al. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil–oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics. 2011;12(3):433–42.PubMedCrossRef
36.
Procopciuc L, Osian G. Lys751Gln XPD and Arg399Gln XRCC1 in Romanians. Association with sporadic colorectal cancer risk and different stages of carcinomas. Chirurgia (Bucur). 2013;108(5):711–8.
37.
Stern MC, Siegmund KD, Conti DV, Corral R, Haile RW. XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Cancer Epidemiol Biomark Prev. 2006;15(12):2384–90.CrossRef
38.
Rezaei H, Motovali-Bashi M, Khodadad K, Elahi A, Emami H, Naddaffnia H. Relationship between XPD Lys 751 Gln polymorphism and colorectal cancer risk: a case-control study in a population-based study. Gastroenterol Hepatol Bed Bench. 2013;6(1):18.PubMedPubMedCentral
39.
Zhang T, Zhang D-M, Zhao D, Hou X-M, Ma S-C, Liu X-J. Lack of association between the XPD Lys751Gln polymorphism and colorectal cancer risk: a meta-analysis. Onco Targets Ther. 2014;7:1255.PubMedPubMedCentralCrossRef
40.
Zhang Y, Ding D, Wang X, Zhu Z, Huang M, He X. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case–control studies. Int J Color Dis. 2011;26(10):1257–64.CrossRef
41.
Kjersem J, Thomsen M, Guren T, Hamfjord J, Carlsson G, Gustavsson B, et al. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin. Pharmacogenomics J. 2016;16(3):272.PubMedCrossRef
42.
Wu W, Zhang W, Qiao R, Chen D, Wang H, Wang Y, et al. Association of XPD polymorphisms with severe toxicity in non–small cell lung cancer patients in a Chinese population. Clin Cancer Res. 2009;15(11):3889–95.PubMedCrossRef
43.
Ruzzo A, Graziano F, Galli F, Giacomini E, Floriani I, Galli F, et al. Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. Sci Rep. 2014;4:6828.PubMedPubMedCentralCrossRef
44.
Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, et al. Sex-related differences in impact on safety of Pharmacogenetic profile for colon cancer patients treated with FOLFOX-4 or XELOX adjuvant chemotherapy. Sci Rep. 2019;9(1):1–9.CrossRef
45.
Gan Y, Li X-R, Chen D-J, Wu J-H. Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population. Asian Pac J Cancer Prev. 2012;13(11):5721–4.PubMedCrossRef
46.
Stoehlmacher J, Park D, Zhang W, Yang D, Groshen S, Zahedy S, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer. 2004;91(2):344.PubMedPubMedCentralCrossRef
47.
Shirota Y, Stoehlmacher J, Brabender J, Xiong Y-P, Uetake H, Danenberg KD, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19(23):4298–304.PubMedCrossRef
48.
Schirripa M, Procaccio L, Lonardi S, Loupakis F. The role of pharmacogenetics in the new ESMO colorectal cancer guidelines. Pharmacogenomics. 2017;18(3):197–200.PubMedCrossRef
49.
Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007;25(10):1247–54.PubMedCrossRef
50.
Pare L, Marcuello E, Altes A, Del Río E, Sedano L, Salazar J, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer. 2008;99(7):1050.PubMedPubMedCentralCrossRef
51.
Chua W, Goldstein D, Lee C, Dhillon H, Michael M, Mitchell P, et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer. 2009;101(6):998–1004.PubMedPubMedCentralCrossRef
52.
Dimberg J, Skarstedt M, Slind Olsen R, Andersson RE, Matussek A. Gene polymorphism in DNA repair genes XRCC 1 and XRCC 6 and association with colorectal cancer in Swedish patients. APMIS. 2016;124(9):736–40.PubMedCrossRef
53.
Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res. 2001;21(4B):3075–9.PubMed
Metadata
Title
Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival
Authors
Hamideh Salimzadeh
Elinor Bexe Lindskog
Bengt Gustavsson
Yvonne Wettergren
David Ljungman
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-06924-z

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue

Research article

Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China

Research article

Sentinel node theory helps tracking of primary lesions of cancers of unknown primary

Research article

Multi-nanolayer drug delivery using radiofrequency plasma technology

Research article

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer

Technical advance

Different ODE models of tumor growth can deliver similar results

Research article

Value of digital mammography in predicting lymphovascular invasion of breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits